Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Researchers have identified antibodies in the blood of survivors that can kill various types of Ebola, providing a potential single treatment against several strains. The study's findings could lead to the development of treatments for Ebola and other related viruses.
Scientists at Virginia Tech Carilion Research Institute have found a way to influence long-term memory formation in the immune system. The researchers discovered that proteins responding to the cells' environment can push effector cells towards memory, leading to the creation of specialized cells to combat specific invading pathogens.
A new University of Birmingham study has found that lower levels of antibodies in saliva are associated with an elevated risk of mortality. The research discovered a negative correlation between IgA secretion rate and all-cause mortality rates, with underlying associations to cancer mortality, particularly non-lung cancers.
A person's first flu infection stimulates key antibody production, which later influences responses to other seasonal strains. Researchers found that early exposure, such as in childhood, can imprint the immune system and shape its response.
A systems biology study of over 400 volunteers found that certain molecular signatures predict strong immune responses to seasonal flu vaccines in both young and elderly individuals. The researchers identified a distinct signature associated with long-lasting antibody responses, which may guide the development of more effective vaccines.
Researchers at the University of Texas at Austin have developed two antibodies to potentially treat or prevent pertussis, a highly contagious respiratory tract infection that affects millions of infants worldwide. The antibodies potently neutralize pertussis toxin, bolstering immune function and rapidly reducing white blood cell counts.
Researchers at Kyoto University have discovered that an antibody called nivolumab may help patients with platinum-resistant ovarian cancer heal themselves by targeting the PD-1 signal. A phase II clinical trial found that most patients treated with nivolumab experienced a median overall survival of 20 months.
Researchers at University of California have successfully created a strain of mosquitoes capable of rapidly introducing malaria-blocking genes into its population, potentially eliminating the disease. The breakthrough uses a gene editing technique that allows for efficient creation of large populations of mosquitoes with this trait.
Researchers at IRCM identified the mechanism of action for a new target in immune-oncology treatments, focusing on natural killer cells and DNAM-1 protein. The discovery could lead to improved therapies using antibodies against TIGIT receptor.
Researchers at the University of Wisconsin-Madison have created an antibody that selectively links to a protein on highly aggressive brain cancer cells, causing them to light up in PET scanners. This breakthrough could lead to improved diagnosis and treatment of glioblastoma multiforme, a deadly form of brain cancer.
Researchers discovered that introducing a specific strain of bacteria into mice with melanoma boosted their immune systems to attack tumor cells. The findings suggest that manipulating gut bacteria can improve immunotherapy outcomes, providing a new approach to treating cancer.
A possible solution to the inflammatory side effects of Alzheimer's immunotherapy has been discovered by researchers from the University of Southampton. They engineered three new antibodies that preserved immunotherapeutic activity while reducing inflammation.
Researchers discovered that anti-PlGF antibody treatments, such as aflibercept, may slow the progression of dry age-related macular degeneration. The study found that PlGF actually worsened retinal damage in mice, but an anti-PlGF treatment provided protection against light-induced degeneration.
A study by Rice University researchers has solved a long-standing mystery about the storage and secretion of blood-clotting factor VIII. The protein is both stored and secreted from a specialized organelle in endothelial cells, which line the walls of blood vessels.
Researchers can improve research and reduce costs by replacing animal-derived antibodies with modern technologies like recombinant antibodies and aptamers. This switch has the potential to save tens of thousands of animals from suffering in laboratories.
Researchers have found that a deadly fish virus, viral hemorrhagic septicemia virus (VHSv), is still circulating in Lake Winnebago, Wisconsin. Despite efforts to slow its spread, the virus can survive in infected fish, potentially leading to future outbreaks.
Researchers have discovered a candidate target for a dengue virus transmission-blocking vaccine, which interferes with the virus's infection of mosquitoes. The target protein, CRVP379, is required during DENV infection in mosquito cells and whole mosquitoes, and its expression levels correlate with the level of DENV infection.
Researchers at The Scripps Research Institute have discovered a way to convert leukemia cells into cancer-killing immune cells using a rare human antibody. The induced NK cells can detect and eliminate cancer cells, offering a potential new therapy for leukemia and possibly other cancers.
A team of researchers from the University of Pennsylvania School of Medicine has elucidated the structure of a protein complex at its root, which may hold therapeutic potential for treating heparin-induced thrombocytopenia (HIT). The study found that an antibody called RTO disrupts this complex, preventing platelet activation and clot ...
A team of researchers found that sialic acid reduces antibody-induced cell killing, offering potential treatment for autoimmune diseases. Antibodies with this sugar structure are detectable more frequently in healthy individuals than those with autoimmune diseases.
A new approach using DNA nanomachines can detect specific antibodies in five minutes, enabling rapid and affordable point-of-care diagnostics for infectious diseases like HIV. This technology promises to reduce healthcare costs and treatment initiation delays.
A team of Caltech biologists has created a non-surgical approach to deliver long-term contraception using a single shot, rendering animals infertile for up to two months. The technique targets the 'master regulator of reproduction,' gonadotropin-releasing hormone (GnRH), neutralizing its effects and preventing conception.
Researchers develop rapid and efficient method to target protein modification, enabling precise attachment of synthetic molecules. This technique has potential applications in antibody-drug conjugates for tumor therapy, outperforming existing methods.
Genetic mutations in Ebola virus appear to block antibody-based treatments from warding off infection. The mutations, or 'escape variants,' have implications for the continued development of therapeutics to treat Ebola virus disease, which has claimed over 11,000 lives in West Africa.
A team of researchers from the USA, England, Australia, and Germany will collaborate on a three-year project to better understand the information processing in germinal centres of lymph nodes. The goal is to gain insights into antibody formation and develop targeted therapeutics for infections.
Patients with autoimmune hepatitis who present with cirrhosis at first diagnosis and those with SLA/LP antibodies have a higher risk of relapse, liver transplant, and reduced life expectancy. The presence of SLA/LP antibodies is linked to poor overall and liver transplant-free survival.
Study finds that certain IgG3 and IgG4 donor-specific HLA antibodies correlate with distinct patterns of antibody-mediated injury to transplanted organs. Patients with mostly IgG3 antibodies have a higher likelihood of organ rejection soon after transplantation, while those with mostly IgG4 antibodies experience delayed rejection.
Researchers developed a paper-based device that changes color to detect Ebola, yellow fever, or dengue viruses. The test takes minutes and doesn't require electricity, providing a potential solution for remote, low-resource areas.
A team of scientists at Scripps Research Institute has devised an improved method to engineer therapeutic proteins into antibodies, which can persist long enough to be useful. The technique mimics evolution and harnesses the power of large numbers to select rare junction segments that allow inserted proteins to fold and function normally.
Scientists have successfully tested a new tumor diagnosis method that uses molecular spies to detect diseased cells and visualize tumors. The method, which combines antibody-based detection with pre-targeting technology, has the potential to improve cancer treatment by using internal radiation.
A licensed technology measures anti-HLA antibody secretion from memory B cells, improving kidney transplant efficiency and preventing rejection. Researchers found high-risk patients using this technique, which complements existing antibody measurement methods.
The HVTN 505 study found that the candidate vaccine induced polyreactive antibodies recognizing both HIV and intestinal microbes. These non-specific antibodies may decrease vaccine effectiveness against HIV.
A new online portal provides a robust online interactive database to address the 'antibody crisis' in molecular biology. The Histone Antibody Specificity Database allows scientists to find reliable antibodies for their research with higher confidence, using validated test results.
A study published in PLOS Pathogens found that older individuals are more susceptible to West Nile virus due to impaired immune responses. The researchers discovered that older mice had delayed antibody responses, reduced helper T cells, and lower chemokine levels, leading to higher viral loads and increased brain damage.
A new database, Histone Antibody Specificity Database, has been launched to improve the accuracy of histone antibodies used in epigenetics research. The database provides validated test results for over 100 commonly used antibodies, allowing researchers to select reliable options for their experiments.
A phase 2 trial found that AS03 and MF59 adjuvants increased immune responses to an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest antibody response. The study suggests AS03 as a first-line adjuvant for H7N9 vaccines in adults.
Researchers at Rockefeller University discovered that high affinity B cells divide faster during the antibody selection process, giving them an advantage. This discovery builds on earlier work and may have important implications for improving vaccines and understanding lymphomas.
A University of Toronto research team discovered a new link between the genetic cause of ALS and its pathology, suggesting that C9orf72's mislocalization leads to TDP-43 buildup. This breakthrough offers new avenues for research and potential treatment or cure.
Researchers have discovered a subset of plasma cells in the bone marrow that serve as an immune archive, preserving a catalog of how the body responded to measles and mumps viruses in childhood. These long-lived cells can provide valuable insights for vaccine designers aiming to create long-lasting antibodies.
Vanderbilt University Medical Center researchers have developed a large panel of antibody treatments against chikungunya, a flu-like illness with debilitating joint pain. The antibodies can be used to treat infected individuals early in the infection, potentially preventing severe symptoms.
Researchers discovered a link between autoimmune diseases and Long QT syndrome, a potentially life-threatening heart condition. Screening and counseling are now recommended for patients with certain medications or abnormal electrolytes.
A new study found that a test can predict which rheumatoid arthritis patients will fail to respond to biologic drugs. Detecting low drug levels and anti-drug antibodies in the bloodstream can help adjust treatments.
Researchers developed a new method to map critical chemical tags on proteins, enabling better understanding of protein formation and function. The technique allows pinpointing phosphates' location and studying unstable amino acids like histidine.
A team led by Associate Professor Shee-Mei Lok at Duke-NUS Medical School discovered an antibody that neutralizes dengue virus serotype 2 (DENV-2), making it harder to kill. The finding could help develop dengue therapeutics and is a significant step towards addressing the global dengue pandemic.
Researchers discovered a human antibody specific to dengue virus serotype 2 that protects mice from the virus, regardless of administration timing. The antibody may act as both a preventative and therapeutic agent by locking viral envelope proteins on the surface, preventing them from entering host cells.
A Stanford study found that narcolepsy may be triggered by a combination of genetic predisposition and infection, particularly with the H1N1 virus. Researchers discovered elevated antibodies in patients who received the Pandemrix flu vaccine, which was associated with an increased risk of narcolepsy.
Researchers at Scripps Research Institute identify new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The study provides ingredients needed to develop treatments for future Marburg outbreaks.
Researchers at The Wistar Institute identified specific mutations in H3N2 viruses that made the 2014-2015 flu vaccine less effective. Antigenic drift, a phenomenon where viruses accumulate mutations to evade immune response, was found to be a key factor.
A single mutation in the H3N2 virus helped it evade the immune system's defenses, making last year's flu vaccine less effective. Researchers have identified this mutation as a key factor in the mismatch between the vaccine strain and circulating strains.
Researchers uncover detailed information on AnAPN1 protein shape and antibody binding sites, enabling the design of more effective mosquito-based vaccines. This breakthrough may lead to a reduced number of infected mosquitoes and eventual disease eradication.
Zhiqiang An received a grant to research how tumors evade therapy, aiming to develop countermeasures for improved immunotherapy success and reduced mortality. The focus is on a type of leukemia affecting tens of thousands in the US.
Researchers found that patients positive for HPV16 E1, E4-7, L1, L2, and E2 antibodies had better overall and progression-free survival compared to those negative. This suggests that these antibodies may be used to identify patients at risk of oropharyngeal cancer recurrence and death.
Scientists developed ICeChIP, a new technique to calibrate chromatin immunoprecipitation (ChIP) experiments with an internal standard. This improves accuracy and reproducibility in epigenetic studies, enabling comparisons between experiments and discovery of new findings, including the prevalence of bivalency in stem cells.
Researchers discovered that Hepatitis C virus variants work together, sacrificing some to protect others from the immune system. This complex interaction, known as antigenic cooperation, could alter vaccine and treatment strategies.
Researchers have discovered a novel antibody insecticide that targets the African malaria mosquito, offering an alternative control strategy to halt the spread of the disease. The antibodies work by targeting a key component of the mosquito's nervous system, killing over 90% of infected insects within a day.
A novel antibody, Ab926, has been discovered that can prevent E. coli from attaching to human cell surfaces and also dislodge bacteria already attached. This antibody works by binding to the side of the FimH pocket, rather than directly competing with free-floating mannose.
A Case Western Reserve University researcher has won a $500,000 NSF CAREER grant to develop tiny sensors capable of detecting insecticides in Lake Erie or determining subtypes of human cancers. The technology combines antibodies with plant viruses to create a large surface area for targeting pollutants or cancer cells.
Scientists at MIT created a new cancer therapy that activates both the innate and adaptive immune systems to attack tumors. The treatment combines an antibody drug with IL-2, which boosts immune responses, resulting in complete tumor disappearance in 80-90% of mice.
Researchers at Texas Biomedical are exploring a novel mechanism for Filovirus detection using llama antibodies, which could lead to more sensitive diagnostic tools for Marburg and Ebola viruses. The goal is to develop streamlined tests that can detect all known and emerging strains of these viruses.
A Phase 1 trial of VSV-ZEBOV, an experimental Ebola vaccine, found it safe and elicited robust antibody responses in all 40 healthy adults who received it. The vaccine showed a favorable safety profile with mild or moderate fever experienced by 30% of participants.